Results 1 to 10 of about 38,022 (310)

The GIP receptor displays higher basal activity than the GLP-1 receptor but does not recruit GRK2 or arrestin3 effectively. [PDF]

PLoS ONE, 2014
Background and objectivesGlucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are important regulators of insulin secretion, and their functional loss is an early characteristic of type 2 diabetes mellitus (T2DM ...
Suleiman Al-Sabah, Munya Al-Fulaij, Ghina Shaaban, Hanadi A Ahmed, Rosalind J Mann, Dan Donnelly, Moritz Bünemann, Cornelius Krasel   +7 more
doaj   +9 more sources

Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor Agonists [PDF]

Endocrinology and Metabolism, 2021
Glucagon-like peptide-1 (GLP-1) receptor agonists are efficacious glucose-lowering medications with salient benefits for body weight and cardiovascular events. This class of medications is now recommended as the top priority for patients with established
Hun Jee Choe, Young Min Cho
doaj   +1 more source

Tolerability and Effectiveness of Switching to Dulaglutide in Patients With Type 2 Diabetes Inadequately Controlled With Insulin Therapy

Frontiers in Endocrinology, 2022
AimsGlucagon‐like peptide 1 (GLP-1) receptor agonists have demonstrated strong glycemic control. However, few studies have investigated the effects of switching from insulin to GLP-1 receptor agonists.
Youngsook Kim, Ji Hye Huh, Minyoung Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee   +5 more
doaj   +1 more source

GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease

Kidney and Dialysis, 2022
Diabetic kidney disease (DKD) represents an important diabetes (DM) complication associated with significant impacts on morbidity, mortality, and quality of life. Recent evidence from cardiovascular and kidney outcome trials has dramatically impacted the
Joshua J. Neumiller, Radica Z. Alicic, Katherine R. Tuttle   +2 more
doaj   +1 more source

Nephroprotective Properties of the Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Receptor Agonists

Biomedicines, 2022
Diabetes mellitus is the leading cause of chronic kidney disease, and about 30–40% of patients with diabetes will develop kidney disease. Incretin hormones have received attention during the past three decades not only as a pharmacotherapy for the ...
Tomislav Bulum
doaj   +1 more source

β-catenin mediates the effect of GLP-1 receptor agonist on ameliorating hepatic steatosis induced by high fructose diet

European Journal of Histochemistry, 2020
The hypoglycemic drug GLP-1 receptor agonist can ameliorate hepatic steatosis but the mechanism is not clear. Intake of high fructose leads to non-alcoholic fatty liver disease by stimulating lipid synthesis, and β-catenin is the key molecule for ...
Zhe Gao, Guang-Yao Song, Lu-Ping Ren, Hui-Juan Ma, Bo-Qing Ma, Shu-Chun Chen   +5 more
doaj   +1 more source

Glucagon-like peptide-1 attenuates diabetes-associated osteoporosis in ZDF rat, possibly through the RAGE pathway

BMC Musculoskeletal Disorders, 2022
Background Diabetes-associated osteoporosis are partly caused by accumulation of advanced glycation endproducts (AGEs). Glucagon-like peptide-1 (GLP-1) has been shown to regulate bone turnover.
Yanzhen Cheng, Peng Liu, Qianru Xiang, Jiamin Liang, Huafeng Chen, Hua Zhang, Li Yang   +6 more
doaj   +1 more source

GLP-1 Receptor: A New Target for Sepsis

Frontiers in Pharmacology, 2021
Patients with sepsis often exhibit hyperglycemia, which increases mortality. glucagon-like peptide-1 receptor agonists (GLP-1RAs) not only regulate blood glucose homeostasis but also improve organ dysfunction, regulate immunity, and control inflammation ...
Fuxun Yang, Fan Zeng, Xiaoxiu Luo, Yu Lei, Jiajia Li, Sen Lu, Xiaobo Huang, Yunping Lan, Rongan Liu   +8 more
doaj   +1 more source

Swiss recommendations of the Society for Endocrinology and Diabetes (SGED/SSED) for the treatment of type 2 diabetes mellitus (2023)

Swiss Medical Weekly, 2023
As a first step, the authors emphasise lifestyle changes (increased physical activity, stopping smoking), blood pressure control, and lowering cholesterol).
Giacomo Gastaldi, Barbara Lucchini, Sebastien Thalmann, Stephanie Alder, Markus Laimer, Michael Brändle, Peter Wiesli, Roger Lehmann, Working group of the SGED/SSED   +8 more
doaj   +1 more source

Activation of GLP-1 Receptor Promotes Bone Marrow Stromal Cell Osteogenic Differentiation through β-Catenin

Stem Cell Reports, 2016
Glucagon-like peptide 1 (GLP-1) plays an important role in regulating bone remodeling, and GLP-1 receptor agonist shows a positive relationship with osteoblast activity.
Jingru Meng, Xue Ma, Ning Wang, Min Jia, Long Bi, Yunying Wang, Mingkai Li, Huinan Zhang, Xiaoyan Xue, Zheng Hou, Ying Zhou, Zhibin Yu, Gonghao He, Xiaoxing Luo   +13 more
doaj   +1 more source